Tricor
Fasting May Not Be Needed Before Cholesterol Test »
"Nov. 12, 2012 -- The requirement to fast before a cholesterol check can be a major inconvenience.
People who forget to fast may be told to reschedule their appointments. For those who remember, sitting in a doctor's waiting room with "...
Read the Fasting May Not Be Needed Before Cholesterol Test article »
Tricor
INDICATIONS
Primary Hypercholesterolemia or Mixed Dyslipidemia
TRICOR is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
Severe Hypertriglyceridemia
TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.
Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.
Important Limitations of Use
Fenofibrate at a dose equivalent to 145 mg of TRICOR was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus [see WARNINGS AND PRECAUTIONS].
DOSAGE AND ADMINISTRATION
General Considerations
Patients should be placed on an appropriate lipid-lowering diet before receiving TRICOR, and should continue this diet during treatment with TRICOR. TRICOR tablets can be given without regard to meals.
The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.
Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of TRICOR if lipid levels fall significantly below the targeted range.
Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 145 mg once daily.
Primary Hypercholesterolemia or Mixed Dyslipidemia
The initial dose of TRICOR is 145 mg once daily.
Severe Hypertriglyceridemia
The initial dose is 48 to 145 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 145 mg once daily.
Impaired Renal Function
Treatment with TRICOR should be initiated at a dose of 48 mg per day in patients having mild to moderately impaired renal function, and increased only after evaluation of the effects on renal function and lipid levels at this dose. The use of TRICOR should be avoided in patients with severe renal impairment [see Use In Specific Populations and CLINICAL PHARMACOLOGY].
Geriatric Patients
Dose selection for the elderly should be made on the basis of renal function [see Use In Specific Populations].
HOW SUPPLIED
Dosage Forms And Strengths
- 48 mg yellow tablets, imprinted with “Abbott “A” logo” and Abbo-Code identification letters “FI”.
- 145 mg white tablets, imprinted with “Abbott “A” logo” and Abbo-Code identification letters “FO”.
Storage And Handling
TRICOR® (fenofibrate tablets) is available in two strengths:
48 mg yellow tablets, imprinted with “Abbott “A” logo” and Abbo-Code identification letters “FI”, available in bottles of 90 (NDC 0074-6122-90).
145 mg white tablets, imprinted with “Abbott “A” logo” and Abbo-Code identification letters “FO”, available in bottles of 90 (NDC 0074-6123-90).
Storage
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).
[See USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.
Manufactured for Abbott Laboratories, North Chicago, IL 60064, U.S.A. by Fournier Laboratories Ireland Limited, Anngrove, Carrigtwohill Co. Cork, Ireland. Revised: 2/2013
Last reviewed on RxList: 2/22/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Tricor Information
Tricor - User Reviews
Tricor User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Tricor sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cholesterol Management
Tips to keep it under control.
Updated & New
